Search
Brimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedThe patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalof oral zavegepant (150 mg bid) in subjects with mild allergic asthma. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesmRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.[L53393] It is the primary ingredient of the RSV vaccine mRESVIA.
Coronavirus Disease 2019 (COVID‑19)
go.drugbank.com/conditions/DBCOND0129755Drugs: Anakinra · Andusomeran · AstraZeneca COVID-19 Vaccine · BNT162B2 Omicron (LP.8.1) · Baricitinib · CX-046684 +26 moreSynonyms: SARS COV2, Sars Cov 2Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS, D-ARTEPPCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsNogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[A263617, A263622] Nogapendekin alfa, in combination with inbakicept, mimics the actions of IL-15, , stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which … Nogapendekin alfa is a human IL-15N72D variant.
Categories: Interleukin-15, Receptors, Interleukin-15Synonyms: Human interleukin 15 (72-aspartic acid) (human il-15 n72>d isoform), Il-15n72d:il-15rec-su/fc soluble complex iBisoctrizole
go.drugbank.com/drugs/DB11262Approved10% [F90]. … Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M [A19212].
Mixtures: SPF 50, Emulsion SPF 50+Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3. … maintenance monotherapy resulted in a 22% reduction in the risk of death.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates